Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins

Abstract

A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.

1 . A composition comprising an  N. meningitidis  serogroup B (NmB) outer membrane preparation mixed with a 287 protein. 
     
     
         2 : The composition of  claim 1  further comprising an ORF40 protein. 
     
     
         3 : The composition of  claim 2  further comprising a different  Neisseria meningitidis  protein. 
     
     
         4 : The composition of  claim 1 , further comprising an protein ORF1 comprising the amino acid sequence of SEQ ID NO:16 or a fragment of at least 10 contiguous amino acids therefrom, and a protein 919 comprising the amino acid sequence of SEQ ID NO:21 or a fragment of at least 10 contiguous amino acids therefrom. 
     
     
         5 : The composition of  claim 3 , where the different  Neisseria meningitidis  protein selected from the group consisting of:
 protein ORF1 comprising the amino acid sequence of SEQ ID NO:16 or a fragment of at least 10 contiguous amino acids therefrom,   protein ORF21 comprising the amino acid sequence of SEQ ID NO:5 or a fragment of at least 10 contiguous amino acids therefrom,   protein ORF46 comprising the amino acid sequence of SEQ ID NO:18 or a fragment of at least 10 contiguous amino acids therefrom,   protein 919 comprising the amino acid sequence of SEQ ID NO:21 or a fragment of at least 10 contiguous amino acids therefrom, and   TbpB comprising the amino acid sequence of SEQ ID NO:15 or a fragment of at least 10 contiguous amino acids therefrom.   
     
     
         6 : The composition of  claim 4 , wherein the  N. meningitidis  serogroup B outer membrane preparation comprises outer membrane vesicles (OMVs). 
     
     
         7 : The composition of  claim 6 , wherein the OMVs are from strain 44/76 of  N. meningitidis.    
     
     
         8 : The composition of  claim 6 , wherein the OMVs are a deoxycholate extract from a  N. meningitidis  serogroup B bacterium. 
     
     
         9 : The composition of  claim 6 , wherein the OMVs comprise 25 μg protein and 2 μg lipopolysaccharide (LPS). 
     
     
         10 : The composition of  claim 5 , wherein the  N. meningitidis  serogroup B outer membrane preparation comprises outer membrane vesicles (OMVs). 
     
     
         11 : The composition of  claim 10 , wherein the OMVs are from strain 44/76 of  N. meningitidis.    
     
     
         12 : The composition of  claim 10 , wherein the OMVs are a deoxycholate extract from a  N. meningitidis  serogroup B bacterium. 
     
     
         13 : The composition of  claim 10 , wherein the OMVs comprise 25 μg protein and 2 μg lipopolysaccharide (LPS). 
     
     
         14 : The composition of any one of  claim 6 ,  7 ,  10 , or  11 , wherein the OMVs are adsorbed on aluminum hydroxide. 
     
     
         15 : The composition of any one of  claim 6 ,  7 ,  10 , or  11 , wherein the composition further comprises one or more of the following components:
 a protective antigen against  Neisseria meningitidis  serogroup A;   a protective antigen against  Neisseria meningitidis  serogroup C;   a protective antigen against  Neisseria meningitidis  serogroup Y;   a protective antigen against  Neisseria meningitidis  serogroup W;   a protective antigen against  Haemophilus influenzae;      a protective antigen against  pneumococcus;      a protective antigen against diphtheria;   a protective antigen against tetanus;   a protective antigen against whooping cough;   a protective antigen against  Helicobacter pylori;      a protective antigen against polio; and/or   a protective antigen against hepatitis B virus.   
     
     
         16 : The composition of any one of  claim 6 ,  7 ,  10 , or  11 , wherein the OMVs and the proteins are combined by simply mixing the OMVs and the proteins. 
     
     
         17 : The composition of any one of  claim 6 ,  7 ,  10 , or  11 , wherein the OMVs and at least one of the proteins are from different  N. meningitidis  serogroup B strains.